SSY GROUP (02005.HK): Stiripentol Suspension Renewed on NRDL
NewTimeSpace News: On 16 November 2026, SSY Group Limited (stock code: 02005) announced that the Group's Stiripentol Dry Suspension has completed its renewal in the 2026 version of China's National Reimbursement Drug List (NRDL) and remains included in the updated list.
The product was approved in 2023 as the first generic stiripentol dry suspension in China, is offered in 250mg and 500mg specifications and was first included in the NRDL in 2024. It is mainly used to treat severe myoclonic epilepsy of infancy, or Dravet syndrome, which was included in China's first batch of rare disease lists in 2018; the dry suspension form suits young children with swallowing difficulties and addresses both medication adherence and individualised dosing.
The Group's stiripentol bulk drug has also been approved for use in marketed preparations, forming an integrated bulk drug and preparation layout. The Group said it has focused on pediatric dosage forms including dry suspensions, oral solutions and granules, covering anti-infectives, respiratory, digestive and nervous system therapies.
- SSY GROUP (02005.HK): Bevantolol Hydrochloride Cleared as API, the Third Domestic Approval
- SSY GROUP (02005.HK): azithromycin tablets pass evaluation
- SSY GROUP (02005.HK): trustee buys 400,000 shares under restricted share award scheme at average HK$2.6122
- CSPC PHARMA (01093.HK): Phase II Trial in China of SYH2066 for RSV Launched
- SSY Group (02005.HK): labetalol API registration approved by China's NMPA